BACKGROUND: The Cambridge pulmonary hypertension outcome review (CAMPHOR) is the first pulmonary hypertension-specific instrument for the assessment of the patient's perceived symptoms, activity limitations and quality of life (QoL). PURPOSE: To produce and validate a Swedish language version of the CAMPHOR. METHODS: Bilingual (n = 5) and lay panels (n = 5) were conducted to translate the CAMPHOR into Swedish. This new questionnaire was then field-tested with 14 patients and finally, it underwent psychometric evaluation by means of a postal validation study involving 38 patients with pulmonary hypertension (PH). RESULTS: Few problems were experienced in translating the CAMPHOR into Swedish. The field-test participants found the scales relevant, comprehensible and easy to complete. Psychometric analyses showed that the Swedish adaptation was successful. The Swedish CAMPHOR scales had good internal consistency. Cronbach's alpha coefficients were 0.92 for the symptoms scale, 0.92 for activity limitations and 0.95 for the quality of life. Predicted correlations with the Nottingham Health Profile provided evidence of the construct validity of the scales. The Swedish scales also indicated known groups validity. CONCLUSIONS: The Swedish version of the CAMPHOR is a reliable and valid measure of the impact of pulmonary hypertension on the lives of affected patients. It is recommended for use in clinical studies and routine practice in pulmonary hypertension patients.
BACKGROUND: The Cambridge pulmonary hypertension outcome review (CAMPHOR) is the first pulmonary hypertension-specific instrument for the assessment of the patient's perceived symptoms, activity limitations and quality of life (QoL). PURPOSE: To produce and validate a Swedish language version of the CAMPHOR. METHODS: Bilingual (n = 5) and lay panels (n = 5) were conducted to translate the CAMPHOR into Swedish. This new questionnaire was then field-tested with 14 patients and finally, it underwent psychometric evaluation by means of a postal validation study involving 38 patients with pulmonary hypertension (PH). RESULTS: Few problems were experienced in translating the CAMPHOR into Swedish. The field-test participants found the scales relevant, comprehensible and easy to complete. Psychometric analyses showed that the Swedish adaptation was successful. The Swedish CAMPHOR scales had good internal consistency. Cronbach's alpha coefficients were 0.92 for the symptoms scale, 0.92 for activity limitations and 0.95 for the quality of life. Predicted correlations with the Nottingham Health Profile provided evidence of the construct validity of the scales. The Swedish scales also indicated known groups validity. CONCLUSIONS: The Swedish version of the CAMPHOR is a reliable and valid measure of the impact of pulmonary hypertension on the lives of affected patients. It is recommended for use in clinical studies and routine practice in pulmonary hypertensionpatients.
Authors: Katarzyna Małaczynska-Rajpold; Anna Smukowska-Gorynia; Alice Heaney; Stephen P McKenna; Magdalena Janus; Aleksander Araszkiewicz; Stanislaw Jankiewicz; Sylwia Slawek-Szmyt; Iga Tomaszewska; Tatiana Mularek-Kubzdela Journal: Cardiol J Date: 2018-10-19 Impact factor: 2.737
Authors: Caio J C S Fernandes; Barbara C S Martins; Carlos V P Jardim; Rozana M Ciconelli; Luciana K Morinaga; Ana Paula Breda; Susana Hoette; Rogério Souza Journal: Health Qual Life Outcomes Date: 2014-08-30 Impact factor: 3.186
Authors: Abílio Reis; James Twiss; Margarida Vicente; Fabienne Gonçalves; Luísa Carvalho; José Meireles; Alzira Melo; Stephen P McKenna; Luís Almeida Journal: Health Qual Life Outcomes Date: 2016-07-26 Impact factor: 3.186
Authors: M Wapenaar; J Twiss; M Wagenaar; P Seijkens; L van den Toorn; J Stepanous; A Heaney; A van den Bosch; K A Boomars Journal: Neth Heart J Date: 2016-06 Impact factor: 2.380